Nucleus RadioPharma Secures AstraZeneca Funding to Advance Personalized Cancer Therapy nextdigitalhealth.com

A leading radiopharmaceutical tech startup, Nucleus RadioPharma, has secured additional capital in a Series A funding round led by AstraZeneca to make targeted theranostics and radiotherapies more accessible for personalized cancer therapy worldwide.

Through the latest funding round, AstraZeneca joined the list of existing investors at Nucleus RadioPharma, including Mayo Clinic, GE Healthcare, Eclipse Ventures, the University of Missouri, Echo Global Granger Management Mercy Health, and Fox Chase Cancer Center.